Quest Diagnostics
662 hedge funds and large institutions have $13.1B invested in Quest Diagnostics in 2018 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 189 increasing their positions, 259 reducing their positions, and 50 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
32% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 50
22% more call options, than puts
Call options by funds: $51.7M | Put options by funds: $42.2M
9% more capital invested
Capital invested by funds: $12B → $13.1B (+$1.08B)
2% more funds holding
Funds holding: 652 → 662 (+10)
0.64% less ownership
Funds ownership: 88.67% → 88.03% (-0.64%)
27% less repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 259
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$104M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$101M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$87M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$73.6M |
| 5 |
Bank of New York Mellon
New York
|
+$67.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$144M |
| 2 |
Goldman Sachs
New York
|
-$92.6M |
| 3 |
APG Asset Management
Amsterdam,
Netherlands
|
-$90.9M |
| 4 |
BlackRock
New York
|
-$70.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$56.2M |
DGX Hedge Fund Activity: Q2 2018 in Review
662 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2018, worth a combined $13.1B — up 8.9% from $12B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new DGX positions and 50 closed out — a net gain of 16 holders — while 189 added to existing stakes and 259 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $104M. The largest seller was AllianceBernstein, cutting an estimated $144M.
- 662 institutional investors held Quest Diagnostics (DGX) as of Q2 2018, up from 652 in Q1 2018.
- Funds reported $13.1B of Quest Diagnostics stock for Q2 2018, up 8.9% quarter-over-quarter.
- 66 funds opened new Quest Diagnostics positions in Q2 2018 and 50 closed out, a net change of +16 holders.
- The largest Quest Diagnostics buyer in Q2 2018 was HealthCor Management, an estimated $104M added.
- The largest Quest Diagnostics seller in Q2 2018 was AllianceBernstein, an estimated $144M sold.
Based on aggregated 13F filings for Q2 2018.